Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

Memorial Sloan Kettering Cancer Center (MSK)

Status: Enrolling

Conditions: Brain Metastases, Adult; Brain Metastases; Metastatic Brain Tumor; Metastatic Brain Cancer

Treatments: Diagnostic Test: CEST-MRF

Study type: Observational

Funder types: Other

Identifiers

NCT05559853

22-191

Details and patient eligibility

About

The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).

Enrollment: 119 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Healthy volunteers [for Study Aim 1 (SA1) and Study Aim 2 (SA2)] will be entered into the study if they meet the following criteria:

• Age ≥ 18 years
• Able to understand and give informed consent
• No known cancer diagnosis

Patients [for Study Aim 1 (SA1)] will be entered into the study if they meet the following criteria:

• Age ≥ 18 years
• Able to understand and give informed consent
• At least one untreated brain metastasis > 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)

Patients [for Study Aim 3 (SA3)] will be entered into the study if they meet the following criteria:

• Age ≥ 18 years
• Able to understand and give informed consent
• At least one untreated brain metastasis > 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)
• Planned SRS treatment

Exclusion criteria

Healthy volunteers (SA1 & SA2) and patients (SA1 & SA3) exclusion criteria:

• Pregnant or breastfeeding women
• Pre-existing medical conditions, including the likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
• Age < 18 years

Trial design

119 participants in 2 patient groups

Participants with Brain Metastases

Description:

Participants will have at least one untreated brain metastasis \> 1cm

Treatment:

Diagnostic Test: CEST-MRF

Healthy participants

Description:

Participants will have no known cancer diagnosis. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.

Treatment:

Diagnostic Test: CEST-MRF